Illumina A Bright Spot In Its Industry

Sometimes a theme can be completely valid, and yet most investors make no money from it. Investing in bleeding edge life sciences research is a good case in point. There is no question that researchers are gaining insights every day that have already led to changes in how the medical community approaches disease and how healthcare companies approach research into new drugs.

What is more questionable is whether individual investors have profited from it all. If you invested in Affymetrix (Nasdaq:AFFX), Caliper (Nasdaq:CALP) or Helicos (Nasdaq:HLCS), you might have a very different perspective on the industry. But, if you have invested in Illumina (Nasdaq:ILMN), you have done quite well over the last five years. And looking at the second quarter, it looks like those who have stuck by Illumina thus far still have a good reason to hang on.

For the complete piece:
http://stocks.investopedia.com/stock-analysis/2010/Illumina-Bright-Prospects-But-Not-For-Investors--ILMN-AFFX-CALP-HLCS-LIFE-RHHBY-LMNX0728.aspx